Abstract:Autoimmune and autoinflammatory diseases account for more than 80 chronic conditions affecting more than 24 million people in the US. Among these autoinflammatory diseases, noninfectious chronic inflammation of the gastrointestinal (GI) tract causes inflammatory bowel diseases (IBDs), primarily Crohn's and ulcerative colitis (UC). IBD is a complex disease, and one hypothesis is that these are either caused or worsened by compounds produced by bacteria in the gut. While traditional approaches have focused on pan immunosuppressive techniques (e.g., steroids), low remission rates, prolonged illnesses, and an increased frequency of surgical procedures have prompted the search for more targeted and precision therapeutic approaches. IBD is a complex disease resulting from both genetic and environmental factors, but several recent studies have highlighted the potential pivotal contribution of gut microbiota dysbiosis. Gut microbiota are known to modulate the immune status of the gut by producing metabolites that are encoded in biosynthetic gene clusters (BGCs) of the bacterial genome. Here, we show a targeted and high-throughput screening of more than 90 biosynthetic genes in 41 gut anaerobes, through downselection using available bioinformatics tools, targeted gene manipulation in these genetically intractable organisms using the Nanoligomer platform, and identification and synthesis of top microbiome targets as a Nanoligomer BGC cocktail (SB_BGC_CK1, abbreviated as CK1) as a feasible precision therapeutic approach. Further, we used a host-directed immune target screening to identify the NF-κB and NLRP3 cocktail SB_NI_112 (or NI112 for short) as a targeted inflammasome inhibitor. We used these top two microbe- and host-targeted Nanoligomer cocktails in acute and chronic dextran sulfate sodium (DSS) mouse colitis and in TNFΔARE/+ transgenic mice that develop spontaneous Crohn's like ileitis. The mouse microbiome was humanized to replicate that in human IBD through antibiotic treatment, followed by mixed fecal gavage from 10 human donors and spiked with IBD-inducing microbial species. Following colonization, colitis was induced in mice using 1 week of 3% DSS (acute) or 6 weeks of 3 rounds of 2.5% DSS induction for a week followed by 1 week of no DSS (chronic colitis model). Both Nanoligomer cocktails (CK1 and NI112) showed a strong reduction in disease severity, significant improvement in disease histopathology, and profound downregulation of disease biomarkers in colon tissue, as assessed by multiplexed ELISA. Further, we used two different formulations of intraperitoneal injections (IP) and Nanoligomer pills in the chronic DSS colitis model. Although both formulations were highly effective, the oral pill formulation demonstrated a greater reduction in biochemical markers compared to IP. A similar therapeutic effect was observed in the TNFΔARE/+ model. Overall, these results point to the potential for further development and testing of this inflammasome-targeting host-directed therapy (NI112) and more personalized microbiome cocktails (CK1) for patients with recalcitrant IBD.

P056 Local nanocarrier delivery of JAK1 siRNA for IBD treatment: an in vivo mouse model

Therapeutic siRNAs Targeting the JAK/STAT Signalling Pathway in Inflammatory Bowel Diseases

Microbiome- and Host Inflammasome-Targeting Inhibitor Nanoligomers Are Therapeutic in the Murine Colitis Model

Microbiome- and Host Inflammasome-Targeting Inhibitor Nanoliogmers are Therapeutic in Murine Colitis Model

Fab'-bearing Sirna TNFα-loaded Nanoparticles Targeted to Colonic Macrophages Offer an Effective Therapy for Experimental Colitis.

Orally Administrated Nucleotide-Delivery Particles from Microfluidics for Inflammatory Bowel Disease Treatment

Oral Nanoparticles of SNX10-shRNA Plasmids Ameliorate Mouse Colitis

An Orally Administrated Nucleotide-Delivery Vehicle Targeting Colonic Macrophages for the Treatment of Inflammatory Bowel Disease

Leaky gut model of the human intestinal mucosa for testing siRNA-based nanomedicine targeting JAK1

Oral Delivery of Sirna Using Fluorinated, Small-Sized Nanocapsules Toward Anti-Inflammation Treatment.

P098 Novel drug candidate for the treatment of Inflammatory Bowel Disease with unique mechanisms of action

Nanoparticles with Surface Antibody Against CD98 and Carrying CD98 Small Interfering RNA Reduce Colitis in Mice.

Efficient and Targeted Drug/sirna Co-Delivery Mediated by Reversibly Crosslinked Polymersomes Toward Anti-Inflammatory Treatment of Ulcerative Colitis (UC)

Efficient treatment of a preclinical inflammatory bowel disease model with engineered bacteria

Oral delivery of infliximab using nano-in-microparticles for the treatment of inflammatory bowel disease

Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin

Targeting delivery of anti-TNFalpha oligonucleotide into activated colonic macrophages protects against experimental colitis.

Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-α RNA interference for IBD therapy.

Engineered Biomimetic Nanovesicles Show Intrinsic Anti-Inflammatory Properties for the Treatment of Inflammatory Bowel Diseases

PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced ColitiS

P111 Efficacy of a novel long-acting lipidated interleukin-22, alone and in combination with anti-TNF treatment, in a murine chronic DSS colitis model